For its third fiscal quarter (ending September 30), Gilead Sciences Inc (NASDAQ: GILD) has reported a 22% increase in E.P.S. from $1.43 a year ago to $1.75 in the current quarter. However, this performance was $-0.16 short of the consensus estimate of $1.91. E.P.S. were $4.70 for the latest four quarters through September 30 versus $2.65 for the same period a year ago — an increase of 77%.
Recent Price Action
Gilead Sciences Inc (NASDAQ: GILD) stock closed at $80.61 on 11/7/23 after a modest decline of -0.7%. The stock has performed in line with the market over the last nine months and has risen 3.7% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, GILD is expected to continue to be a major Value Builder.
Gilead Sciences has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Gilead Sciences has a neutral Power Rating of 45 but a poor Appreciation Score of 26, producing the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment